← Leaderboards
Joseph P Balthasar
State University Of New York At Buffalo
$10,000,685
Attributed
$11,521,922
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,521,922 · 7
By mechanism
R01$11,521,922 · 7
Top collaborators
- Dhaval K Shah8 shared
Others in their field
Top investigators on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Sharon A Nachman · Johns Hopkins University$194,646,762
- Carol Nesel · Westat$147,274,423
- Barbara Driver · Westat, Inc.$103,746,400
- Ronald T Mitsuyasu · University Of California Los Angeles$99,239,507
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
Research focus
Drug KineticsAntibodiesIn VitroEvaluationUnited StatesMouse ModelIn VivoTumorDoseSafetyMonoclonal AntibodiesMalignant NeoplasmsCessation Of LifeInvestigationAffinityMathematical ModelPreventDesignBindingToxic EffectPharmacodynamicsCatabolismCytotoxicityCells
Grant awards (34)
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia$427,572
R01 · FY2025 · CA · contact PI
Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization$361,459
R01 · FY2025 · CA · contact PI
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia$406,193
R01 · FY2024 · CA · contact PI
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors$344,980
R01 · FY2024 · CA · contact PI
Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization$343,449
R01 · FY2024 · CA · contact PI
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia$426,903
R01 · FY2023 · CA · contact PI
Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization$367,340
R01 · FY2023 · CA · contact PI
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors$355,916
R01 · FY2023 · CA · contact PI
Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization$355,991
R01 · FY2022 · CA · contact PI
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors$355,425
R01 · FY2022 · CA · contact PI
Catch and Release Immunotoxins: CAR-Bombs for Cancer$364,227
R01 · FY2021 · CA · contact PI
Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization$363,287
R01 · FY2021 · CA · contact PI
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors$362,722
R01 · FY2021 · CA · contact PI
Catch and Release Immunotoxins: CAR-Bombs for Cancer$363,056
R01 · FY2020 · CA · contact PI
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors$362,764
R01 · FY2020 · CA · contact PI
Catch and Release Immunotoxins: CAR-Bombs for Cancer$352,249
R01 · FY2019 · CA · contact PI
Catch and Release Immunotoxins: CAR-Bombs for Cancer$360,914
R01 · FY2018 · CA · contact PI
Catch and Release Immunotoxins: CAR-Bombs for Cancer$375,789
R01 · FY2017 · CA · contact PI
Pharmacology and Bioengineering of New Treatment of ITP$353,204
R01 · FY2010 · HL · contact PI
Pharmacology and Bioengineering of New Treatment of ITP$353,204
R01 · FY2009 · HL · contact PI
Pharmacokinetic strategies to optimize IP chemotherapy$255,967
R01 · FY2009 · CA · contact PI
Pharmacology and Bioengineering of New Treatment of ITP$353,204
R01 · FY2008 · HL · contact PI
Pharmacokinetic strategies to optimize IP chemotherapy$255,609
R01 · FY2008 · CA · contact PI
Pharmacology and Bioengineering of New Treatment of ITP$367,829
R01 · FY2007 · HL · contact PI
FcRn Inhibitors for Antibody-Mediated Immune Conditions$327,007
R01 · FY2007 · AI · contact PI
Pharmacokinetic strategies to optimize IP chemotherapy$255,262
R01 · FY2007 · CA · contact PI
FcRn Inhibitors for Antibody-Mediated Immune Conditions$336,774
R01 · FY2006 · AI · contact PI
Pharmacokinetic strategies to optimize IP chemotherapy$277,164
R01 · FY2006 · CA · contact PI
FcRn Inhibitors for Antibody-Mediated Immune Conditions$344,878
R01 · FY2005 · AI
FcRn Inhibitors for Antibody-Mediated Immune Conditions$344,878
R01 · FY2004 · AI
Pharmacology and bioengineering of new treatments of ITP$227,412
R01 · FY2004 · HL
Pharmacology and bioengineering of new treatments of ITP$268,083
R01 · FY2003 · HL
Pharmacology and bioengineering of new treatments of ITP$268,567
R01 · FY2002 · HL
Pharmacology and bioengineering of new treatments of ITP$282,644
R01 · FY2001 · HL